

# Flowcharts for EDA Chairman Decree 450 for the year 2023

## Year 2025

**Code: EDREX:NP.CAPP.064**

**Version No: 5**


**Issue Date: 9/1/2025**


**Effective date: 9/1/2025**

## Table of Contents

EDA Chairman Decree (450/2023) Flowchart for Locally Manufactured Generic Products with assessment timelines.....	3
EDA Chairman Decree (450/2023) Flowchart for Imported Products marketed in one of SRAs or WHO-Prequalified with assessment timelines .....	6
EDA Chairman Decree (450/2023) Flowchart for Imported Products from non-reference country and not marketed in one of reference countries with assessment timelines .....	9
EDA Chairman Decree (450/2023) Flowchart of Imported products approved from FDA and EMA in addition to one of the SRAs or WHO prequalified with assessment timelines (Fast Track) .....	12
EDA Chairman Decree (450/2023) Flowchart of Imported products approved from FDA or EMA in addition to one of the SRAs or WHO prequalified with assessment timelines (Fast Track) .....	15
EDA Chairman Decree (450/2023) Flowchart for Imported Products marketed in one of SRAs or WHO-Prequalified with assessment timelines (Fast Track) .....	18
EDA Chairman Decree (450/2023) Flowchart for Imported Products from non-reference country and not marketed in one of reference countries with assessment timelines (Fast Track) .....	21
EDA Chairman Decree (450/2023) Flowchart for Locally Manufactured Generic Products with assessment timelines (Fast Track).....	24
Emergency Use Approval of Locally Manufactured Generic Products Flowchart with assessment timelines ...	27
Emergency Use Approval of Imported Products Flowchart with assessment timelines .....	29
Locally Manufactured Generic Products' Timeframes .....	31
Imported Products' Timeframes .....	34
Abbreviations:.....	37
Document History:.....	37

## EDA Chairman Decree (450/2023) Flowchart for Locally Manufactured Generic Products with assessment timelines





- Notes:

\*In case of locally manufactured human pharmaceutical products intended for tender and export or for export only, the company shall be notified of the status of the product from the Box **within 15 working days** from the date of receiving the fulfilled and correct registration request.

- Applicant has to submit **Module 1** within 33 months (except in case III Track A: 21 months) from date of pharmacovigilance approval or first pricing certificate whichever is the latest **and** within 33 months from registration request approval (or from Specialized Scientific evaluation committee approval) in case of products registered for Export only.


- The declared working days are the maximum time needed for the process to be completed.


- Applicant Time:

\*\*The Applicant submits the scientific file to Scientific Data & Drug development for human pharmaceutical evaluation unit within 30 WDs from registration request approval (In case the product does not have a scientific reference with the same pharmaceutical form, concentration or method of administration).

\*\*\*Applicant submits to naming unit, pharmacovigilance and pricing within 30 WDs from registration request approval (or from Specialized Scientific evaluation committee approval).

**EDA Chairman Decree (450/2023) Flowchart for Imported Products marketed in one of SRAs or WHO-Prequalified with assessment timelines**







- Applicant Time:
  - \* Applicant submits to naming unit, pharmacovigilance and pricing within 30 WDs from registration request approval
  - Applicant has to submit the updated Module 1 within 6 months from date of pharmacovigilance approval or first pricing certificate whichever is the latest.
- The declared working days are the maximum time needed for the process to be completed.



**EDA Chairman Decree (450/2023) Flowchart for Imported Products from non-reference country and not marketed in one of reference countries with assessment timelines**






- Applicant Time:


- \* Applicant submits to naming unit, pharmacovigilance and pricing within 30 WDs from registration request approval

- Applicant has to submit the updated Module 1 within 6 months from date of pharmacovigilance approval or first pricing certificate whichever is the latest.

- The declared working days are the maximum time needed for the process to be completed.


**EDA Chairman Decree (450/2023) Flowchart of Imported products approved from FDA and EMA in addition to one of the SRAs or WHO prequalified with assessment timelines (Fast Track)**






- Applicant Time:
  - \* Applicant submits to naming unit, pharmacovigilance and pricing within 15 WDs from registration request approval
  - Applicant has to submit the Registration Dossier within 30 WD from date of Trade Name approval.
- The declared working days are the maximum time needed for the process to be completed.

**EDA Chairman Decree (450/2023) Flowchart of Imported products approved from FDA or EMA in addition to one of the SRAs or WHO prequalified with assessment timelines (Fast Track)**









- Applicant Time:
  - \* Applicant submits to naming unit, pharmacovigilance and pricing within 15 WDs from registration request approval
  - Applicant has to submit the Registration Dossier within 30 WD from date of Trade Name approval
- The declared working days are the maximum time needed for the process to be completed.

**EDA Chairman Decree (450/2023) Flowchart for Imported Products marketed in one of SRAs or WHO-Prequalified with assessment timelines (Fast Track)**






- Applicant Time:


- \* Applicant submits to naming unit, pharmacovigilance and pricing within 15 WDs from registration request approval.

- Applicant has to submit the Registration Dossier within 2 months from Trade Name Approval.

- The declared working days are the maximum time needed for the process to be completed.


**EDA Chairman Decree (450/2023) Flowchart for Imported Products from non-reference country and not marketed in one of reference countries with assessment timelines (Fast Track)**






- Applicant Time:
  - \* Applicant submits to naming unit, pharmacovigilance and pricing within 15 WDs from registration request approval.
  - Applicant has to submit the Registration Dossier within 2 months from Trade Name Approval.
- The declared working days are the maximum time needed for the process to be completed.

**EDA Chairman Decree (450/2023) Flowchart for Locally Manufactured Generic Products with assessment timelines (Fast Track)**







- Applicant Time:


- \* The Applicant submits the scientific file to Scientific Data & Drug development for human pharmaceutical evaluation unit within 15 WDs from registration request approval (Incase the product does not have a scientific reference with the same pharmaceutical form, concentration or route of administration).


- \*\* Applicant submits to naming unit, pharmacovigilance and pricing within 15 WDs from registration request approval or specialized scientific evaluation approval.

- Applicant has to submit the Registration Dossier within 33 WDs from date of first pricing certificate.

- The declared working days are the maximum time needed for the process to be completed.

### Emergency Use Approval of Locally Manufactured Generic Products Flowchart with assessment timelines







- Assessment timelines start from receiving complete files from applicants
- Total Assessment Timeline = maximum 44 WDs (without consideration of the time required for preparation of applicant's responses to requests).

\*Bioequivalence study approval is a condition for the commercial batch release (if applicable)

### Emergency Use Approval of Imported Products Flowchart with assessment timelines





- Assessment timelines start from receiving complete files from applicants
- Total Assessment Timeline = maximum 24 WDs (without consideration of the time required for preparation of applicant’s responses to requests).

\*Bioequivalence study approval is a condition for the commercial batch release (if applicable)

## Locally Manufactured Generic Products' Timeframes

### EDA's Assessment Timeframe:

Application type	Application	Pricing +Naming+ PV	Screening &Evaluation
local Generic	31	90	208
local Generic (Fast Track)	18	30	145

\*The timeline mentioned above does not include the time needed for the applicant to fulfill the comments.

### Registration Assessment Time Frames Breakdowns:

Procedure/Time Frame for Files submitted according to	Case I & III (Normal Track)			Case II (Fast Track)
	Module 3 (In Technical Affairs Administration)	Module 5 (In Bioequivalence Unit)	Module 1 (In Regulatory Affairs Administration)	
1 Screening <sup>(1)</sup>	15 WDs	5 WDs		15 WDs
2 Technical Evaluation <sup>(2)</sup>	1 <sup>st</sup> Evaluation and sending letter of comments. = 40 WDs Review of 1 <sup>st</sup> Suppl. Doc.= 15 WDs Review of 2 <sup>nd</sup> Suppl. Doc.= 15 WDs	1 <sup>st</sup> Evaluation and sending letter of comments. = 40 WDs Review of 1 <sup>st</sup> Suppl. Doc.= 5 WDs Review of 2 <sup>nd</sup> Suppl. Doc.= 5 WDs		1 <sup>st</sup> Evaluation and sending letter of comments. = 40 WDs Review of 1 <sup>st</sup> Suppl. Doc.= 10 WDs Review of 2 <sup>nd</sup> Suppl. Doc.= 10 WDs
3 Approval Release from complete dossier	5 WDs	5 WDs		10 WDs
4 Final Review of Registration Dossier			1 <sup>st</sup> Evaluation and sending letter of comments. = 30 WDs Review of 1 <sup>st</sup> Suppl. Doc.= 15 WDs Review of 2 <sup>nd</sup> Suppl. Doc.= 15 WDs	60 WDs
5 Presentation to Technical Committee and MA release			30 WDs	

(1) **Screening:** Review of the technical study by the relevant division (in Normal Track) / review of the registration dossier by Administration of Regulatory Affairs of Human Pharmaceutical Products (in Fast Track) to check its completeness to proceed to the technical assessment process or not.

(2) **Technical Evaluation:** Detailed technical review and assessment of the technical study.



### Applicants Completions Time Frames Breakdowns:

	Division	Case I & III (Normal Track)	Case II (Fast Track)
1	<b>Bioequivalence Unit</b>	The company is committed to submitting the completions within <b>30 days</b> from the date of sending the completions, <b>renewed once</b> , provided that the total completion period doesn't exceed <b>60 days</b> .	<b>All relevant Divisions involved in the Assessment</b>  The company is committed to submitting the completions within <b>3 months</b> from the date of sending the completions, <b>renewed once</b> , provided that the total completion period doesn't exceed <b>6 months</b> .
2	<b>Technical Affairs Administration</b>	The company is committed to submitting the completions within <b>45 days</b> from the date of sending the completions, <b>renewed once</b> , provided that the total completion period doesn't exceed <b>90 days</b> .	
3	<b>Regulatory Affairs Administration</b>	The company is committed to submitting the completions within <b>30 days</b> from the date of sending the completions, <b>renewed once</b> , provided that the total completion period doesn't exceed <b>60 days</b> .	The company is committed to submitting the completions within <b>30 days</b> from the date of sending the completions, <b>renewed once</b> , provided that the total completion period doesn't exceed <b>60 days</b> .

**\*In the event that the total deadline for required completion is exceeded, the company is obligated to pay service consideration for extending the deadline for completing completions for the General Administration of Human Pharmaceuticals Registration.**

## Imported Products' Timeframes

### EDA's Assessment Timeframe:

Application type	Application	Pricing +Naming+ PV	Screening &Evaluation
Imported Products marketed in one of SRAs or WHO-Prequalified	31	90	165
Imported from non-reference country and not marketed in one of the reference countries	31 (After reviewing site master file and module 3 and inspection on the factory overseas)	90	210
Imported products approved from FDA & EMA in addition to one of the SRAs or WHO prequalified (Fast track)	12	30	25
Imported products approved from FDA or EMA in addition to one of the SRAs or WHO prequalified (Fast track)	12	30	50
Imported Products marketed in one of SRAs or WHO-Prequalified with assessment timelines (Fast Track)	18	30	74
Imported from non-reference country and not marketed in one of the reference countries (Fast Track)	20 (After reviewing site master file and Module 3 and inspection on the factory overseas)	30	145

\*The timeline mentioned above does not include the time needed for the applicant to fulfill the comments.

**Registration Assessment Time Frames Breakdowns:**

Procedure/Time Frame for Files submitted according to	Case I & III (Normal Track)		Case II (Fast Track)			
	Imported from Reference Country	Imported from Non- Reference Country and Not marketed in Reference Country	Track A	Track B	Track C Imported from reference country	Track C Imported from non-reference country & not marketed in reference country
1 Screening <sup>(1)</sup>	20 WDs	30 WDs	3 WDs	6 WDs	9 WDs	15 WDs
2 Distribution and Technical Assessment <sup>(2)</sup>	1 <sup>st</sup> Evaluation and sending letter of comments. = 25 WDs Review of 1 <sup>st</sup> Suppl. Doc. = 10 WDs Review of 2 <sup>nd</sup> Suppl. Doc. = 10 WDs	1 <sup>st</sup> Evaluation and sending letter of comments. = 40 WDs Review of 1 <sup>st</sup> Suppl. Doc. = 20 WDs Review of 2 <sup>nd</sup> Suppl. Doc. = 20 WDs	1 <sup>st</sup> Evaluation and sending letter of comments. = 6 WDs Review of 1 <sup>st</sup> Suppl. Doc. = 2 WDs Review of 2 <sup>nd</sup> Suppl. Doc. = 2 WDs	1 <sup>st</sup> Evaluation and sending letter of comments. = 12 WDs Review of 1 <sup>st</sup> Suppl. Doc. = 4 WDs Review of 2 <sup>nd</sup> Suppl. Doc. = 4 WDs	1 <sup>st</sup> Evaluation and sending letter of comments. = 20 WDs Review of 1 <sup>st</sup> Suppl. Doc. = 5 WDs Review of 2 <sup>nd</sup> Suppl. Doc. = 5 WDs	1 <sup>st</sup> Evaluation and sending letter of comments. = 40 WDs Review of 1 <sup>st</sup> Suppl. Doc. = 10 WDs Review of 2 <sup>nd</sup> Suppl. Doc. = 10 WDs
3 Approval Release from complete dossier	10 WDs	10 WDs	5 WDs	10 WDs	10 WDs	10 WDs
4 Final Review of Registration Dossier	1st Evaluation and sending letter of comments. = 30 WDs Review of 1 <sup>st</sup> Suppl. Doc. = 15 WDs Review of 2 <sup>nd</sup> Suppl. Doc. = 15WDs	1st Evaluation and sending letter of comments. = 30 WDs Review of 1 <sup>st</sup> Suppl. Doc. = 15 WDs Review of 2 <sup>nd</sup> Suppl. Doc. = 15WDs	7 WDs	14 WDs	25 WDs	60 WDs
5 Presentation to Technical Committee and MA release	30 WDs	30 WDs				

(1) **Screening:** Review of the registration dossier by Administration of Regulatory Affairs of Human Pharmaceutical Products to check its completeness to proceed to the technical assessment process or not.

(2) **Technical Evaluation:** Detailed technical review and assessment of the registration dossier.

### Applicant completions Time Frames Breakdowns:

	Division	Case I & III (Normal Track)	Case II (Fast Track)
1	All relevant Divisions involved in the Assessment	The company is committed to submitting the completions within <b>45 days</b> from the date of sending the completions, <b>renewed once</b> , provided that the total completion period doesn't exceed <b>90 days</b> .	The company is committed to submitting the completions within <b>3 months</b> from the date of sending the completions, <b>renewed once</b> , provided that the total completion period doesn't exceed <b>6 months</b> .
3	Regulatory Affairs Administration	The company is committed to submitting the completions within <b>30 days</b> from the date of sending the completions, <b>renewed once</b> , provided that the total completion period doesn't exceed <b>60 days</b> .	The company is committed to submitting the completions within <b>30 days</b> from the date of sending the completions, <b>renewed once</b> , provided that the total completion period doesn't exceed <b>60 days</b> .

**\*In the event that the total deadline for required completion is exceeded, the company is obligated to pay service consideration for extending the deadline for completing completions for the General Administration of Human Pharmaceuticals Registration.**

### **Abbreviations:**

- RMP: Risk Management Plan
- PSMF: Pharmacovigilance System Master File
- WD: Working Days
- SRA: Stringent regulatory authority
- Suppl.: Supplementary
- Doc.: Documents

### **Document History:**

Version Number	Issue Date	Summary of Change
1	13/8/2023	New Issue
2	18/12/2023	Updating the receiving steps of registration dossier and timelines according to version 2 of EDA Chairman Decree 450/2023 regulatory guide
3	15/4/2024	Addition of Rolling and One Submission General flowcharts
4	4/8/2024	<ul style="list-style-type: none"> <li>• Clarification in rolling submission “The applicant submits Module 1 to Regulatory Affairs administration”</li> <li>• Clarification of EDA’s Assessment Timeframes</li> </ul>
5	9/1/2025	<ul style="list-style-type: none"> <li>• Update the registration process for locally manufactured products by stipulating that product analysis occurs subsequent to the issuance of the MA license and is a mandatory requirement for the release of the product in the market (page 3-4)                             <ul style="list-style-type: none"> <li>• Removal of General Flowcharts</li> </ul> </li> <li>• Addition of Locally manufactured products timeframe (Page 31-33)</li> <li>• Addition of Imported products timeframe (Page 34-36)</li> </ul>